SCHEMBL1384356

SCHEMBL1384356

CSc1nccc(-c2c(-c3ccc(F)cc3)nc3nn(CCCOC4CCCCO4)cc3c2-c2ccc(F)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
TGFBR1 P36897 2/20 0.37
TGFBR2 P37173 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CSNK1E P49674 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
CSNK1D P48730 2/20 0.33
P2RX3 P56373 1/20 0.33
JAK3 P52333 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386172 0.86 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL2931628 0.85 L3MBTL1 (0.39) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL1384645 0.82 MET (0.40) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL1385618 0.81 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11L3MBTL1
SCHEMBL2927278 0.80 L3MBTL1 (0.40) MAPK14MAPK13MAPK12MAPK11L3MBTL1
SCHEMBL1384569 0.80 L3MBTL1 (0.39) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL2928707 0.79 ADORA3 (0.36) MAPK14TGFBR1TGFBR2L3MBTL1P2RX3
SCHEMBL1386294 0.76 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL1386149 0.75 TGFBR1 (0.37) MAPK14MAPK13MAPK12MAPK11TGFBR1
SCHEMBL1386960 0.72 KDM4C (0.39) TGFBR1TGFBR2L3MBTL1P2RX3MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.